Saturday, October 3, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· April 14, 2026

POET Technologies Provides Clarity on its Passive Foreign Investment Company (PFIC) Status

View original at globenewswire.com
POET Technologies Provides Clarity on its Passive Foreign Investment Company (PFIC) Status Commits to Taking Actions to Address Potential Tax Consequences to U.S…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Board of Directors has declared its intention to move the Company's headquarters to and redomicile the Company in the U.S. to eliminate future PFIC classification possibility

    60% confidence
  • The Company believes that it will not qualify as a PFIC in 2026

    60% confidence
  • QEF election with respect to POET for fiscal year 2025 is expected to result in zero income inclusion for U.S. shareholders

    60% confidence
  • U.S. shareholders that make QEF election for fiscal year 2025 are not expected to have current income inclusions for fiscal year 2025

    60% confidence
  • POET will be treated as a PFIC for the year ended December 31, 2025 based on income and assets

    60% confidence
  • Company believes it will not be a PFIC for fiscal year ending December 31, 2026

    60% confidence
  • POET's Optical Interposer-based products are lower cost, consume less power, are smaller in size and are readily scalable to high production volumes compared to comparable products

    60% confidence
  • POET does not expect to have any earnings and profits for fiscal year 2025 due to net loss

    60% confidence
  • Redomiciling matter will be placed on agenda for shareholder approval at Annual General and Special Meeting on June 26, 2026 if shareholder approval is required

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com